{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:03:18Z","timestamp":1791475398663,"version":"4.3.4"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Degeneration of dopaminergic, nigrostriatal neurons is the hallmark of Parkinson disease (PD), and PET quantification of dopamine transporters is a widely accepted method for differential diagnosis between idiopathic PD and essential tremor. [<jats:sup>18<\/jats:sup>F]PR04.MZ is a new PET tracer with excellent imaging properties allowing for precise quantification of striatal and extrastriatal dopamine transporter. Here we describe our initial experience with [<jats:sup>18<\/jats:sup>F]PR04.MZ PET\/CT in a larger cohort of healthy controls and PD patients as a proof-of-concept study for this tracer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Eighteen healthy subjects, 19 early PD patients (Hoehn-Yahr I\u2013II), and 13 moderate-advanced PD patients (Hoehn-Yahr III\u2013IV) underwent static PET\/CT scans 60 to 90 minutes after injection of 5.16 \u00b1 1.03 mCi (191 \u00b1 38 MBq) [<jats:sup>18<\/jats:sup>F]PR04.MZ. Specific binding ratios (SBRs) were calculated for caudate nucleus, anterior putamen, posterior putamen, substantia nigra (SNpc), compared between different groups and correlated with clinical ratings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>[<jats:sup>18<\/jats:sup>F]PR04.MZ showed very high and specific uptake in the putamen, caudate, and substantia nigra pars compacta and very low nonspecific binding in other brain regions, and SBR values for the control group were 22.3 \u00b1 4.1, 19.1 \u00b1 3.5, and 5.4 \u00b1 1.2, respectively. A reduction of SBR values was observed in all regions and in both initial and moderate PD, ranging from 35% to 89% (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). The observed pattern of reduction was posterior putamen &gt; anterior putamen &gt; substantia nigra pars compacta &gt; caudate, with contralateral posterior putamen being the most affected region. Rostrocaudal depletion gradient was evident in all PD patients and progression correlated with motor manifestations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>[<jats:sup>18<\/jats:sup>F]PR04.MZ PET\/CT is a highly sensitive imaging modality for the detection of dopaminergic deficit in nigrostriatal pathways in PD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003430","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T18:26:38Z","timestamp":1608056798000},"page":"119-124","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["[18F]PR04.MZ PET\/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease"],"prefix":"10.1097","volume":"46","author":[{"given":"Carlos","family":"Juri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasko","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Riss","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Soza-Ried","sequence":"additional","affiliation":[{"name":"Positronpharma SA, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlette","family":"Haeger","sequence":"additional","affiliation":[{"name":"Positronpharma SA, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Pruzzo","sequence":"additional","affiliation":[{"name":"Positronpharma SA, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"R\u00f6sch","sequence":"additional","affiliation":[{"name":"Institute of Nuclear Chemistry, Johannes Gutenberg-University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Chana-Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","article-title":"Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria","volume":"8","year":"2009","journal-title":"Lancet Neurol"},{"issue":"suppl 3","key":"bib2-20250621","first-page":"S425","article-title":"SPECT imaging of the dopaminergic system in (premotor) Parkinson\u2019s disease","volume":"13","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nrneurol.2014.123","article-title":"Parkinson disease: can dopamine transporter imaging define early PD?","volume":"10","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neubiorev.2015.09.007","article-title":"Neuroimaging of Parkinson\u2019s disease: expanding views","volume":"59","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/mds.26907","article-title":"Molecular imaging to track Parkinson\u2019s disease and atypical parkinsonisms: new imaging frontiers","volume":"32","year":"2017","journal-title":"Mov Disord"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/14737175.2016.1135056","article-title":"The role of biomarkers and imaging in Parkinson\u2019s disease","volume":"16","year":"2016","journal-title":"Expert Rev Neurother"},{"issue":"suppl 1","key":"bib7-20250621","first-page":"68","article-title":"Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson\u2019s disease","volume":"184","year":"2003","journal-title":"Exp Neurol"},{"key":"bib8-20250621","first-page":"323","article-title":"Positron emission tomography neuroimaging in Parkinson\u2019s disease","volume":"3","year":"2011","journal-title":"Am J Transl Res"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.nbd.2010.03.006","article-title":"Progression of dopaminergic depletion in a model of MPTP-induced parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study","volume":"38","year":"2010","journal-title":"Neurobiol Dis"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJM198804073181402","article-title":"Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson\u2019s disease. Pathophysiologic and clinical implications","volume":"318","year":"1988","journal-title":"N Engl J Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ana.23798","article-title":"Validation of nigrostriatal positron emission tomography measures: critical limits","volume":"73","year":"2013","journal-title":"Ann Neurol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.23939","article-title":"Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques","volume":"74","year":"2013","journal-title":"Ann Neurol"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14737175.2017.1256205","article-title":"Clinical utility of DaTscan\u2122 imaging in the evaluation of patients with parkinsonism: a US perspective","volume":"17","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/mds.20112","article-title":"Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes","volume":"19","year":"2004","journal-title":"Mov Disord"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"e005122","DOI":"10.1136\/bmjopen-2014-005122","article-title":"Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials","volume":"4","year":"2014","journal-title":"BMJ Open"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00259-019-04594-z","article-title":"Pharmacokinetic evaluation of [(18)F]PR04.MZ for PET\/CT imaging and quantification of dopamine transporters in the human brain","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13550-018-0450-0","article-title":"Dopamine transporter imaging with [(18)F]FE-PE2I PET and [(123)I]FP-CIT SPECT\u2014a clinical comparison","volume":"8","year":"2018","journal-title":"EJNMMI Res"},{"issue":"suppl 1","key":"bib18-20250621","first-page":"3","article-title":"Advantages and disadvantages of PET and SPECT in a busy clinical practice","volume":"19","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"e11067","DOI":"10.1371\/journal.pone.0011067","article-title":"Genomic features of the human dopamine transporter gene and its potential epigenetic states: implications for phenotypic diversity","volume":"5","year":"2010","journal-title":"PLoS One"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1523\/JNEUROSCI.1391-15.2015","article-title":"Brain region-specific trafficking of the dopamine transporter","volume":"35","year":"2015","journal-title":"J Neurosci"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/sj.jcbfm.9600439","article-title":"Quantification of dopamine transporter binding using [18F]FP-beta-CIT and positron emission tomography","volume":"27","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2967\/jnumed.111.101626","article-title":"Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I","volume":"53","year":"2012","journal-title":"J Nucl Med"},{"key":"bib23-20250621","first-page":"90","article-title":"The story of the dopamine transporter PET tracer LBT-999: from conception to clinical use","volume":"6","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/cmdc.200900177","article-title":"Ex vivo and in vivo evaluation of [18F]PR04.MZ in rodents: a selective dopamine transporter imaging agent","volume":"4","year":"2009","journal-title":"ChemMedChem"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bmcl.2011.10.053","article-title":"Characterisation of [11C]PR04.MZ in Papio anubis baboon: a selective high-affinity radioligand for quantitative imaging of the dopamine transporter","volume":"22","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/RLU.0000000000000868","article-title":"Imaging nigrostriatal dopaminergic deficit in Holmes tremor with 18F-PR04.MZ-PET\/CT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib27-20250621","article-title":"Quantification of striatal dopamine transporters with [18F]PR04.MZ in patients with progressive supranuclear palsy and Parkinson\u2019s disease","volume":"31","year":"2016","journal-title":"Mov Disord"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/RLU.0000000000002251","article-title":"The pattern of striatal dopamine depletion as a prognostic marker in de novo Parkinson disease","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","article-title":"Brain dopamine and the syndromes of Parkinson and Huntington clinical, morphological and neurochemical correlations","volume":"20","year":"1973","journal-title":"J Neurol Sci"},{"issue":"Pt 6","key":"bib30-20250621","first-page":"1823","article-title":"Striatonigral degeneration. A clinicopathological study","volume":"113","year":"1990","journal-title":"Brain"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity","volume":"114","year":"1991","journal-title":"Brain"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/RLU.0000000000000638","article-title":"Differential alterations of dopamine transporter in the striatum and midbrain in patients with parkinsonian syndrome","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1039\/b902863c","article-title":"Synthesis and monoamine uptake inhibition of conformationally constrained 2beta-carbomethoxy-3beta-phenyl tropanes","volume":"7","year":"2009","journal-title":"Org Biomol Chem"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"e55031","DOI":"10.1371\/journal.pone.0055031","article-title":"Binding of the radioligand SIL23 to \u03b1-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2009.06.042","article-title":"In vitro characterisation of BF227 binding to alpha-synuclein\/Lewy bodies","volume":"617","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/acs.jmedchem.5b00571","article-title":"Design, synthesis, and characterization of 3-(benzylidene)indolin-2-one derivatives as ligands for \u03b1-synuclein fibrils","volume":"58","year":"2015","journal-title":"J Med Chem"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/mds.25975","article-title":"Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts","volume":"29","year":"2014","journal-title":"Mov Disord"},{"key":"bib38-20250621","first-page":"721","article-title":"Dopamine controls Parkinson\u2019s tremor by inhibiting the cerebellar thalamus","volume":"140","year":"2017","journal-title":"Brain"},{"issue":"suppl 7","key":"bib39-20250621","first-page":"S43","article-title":"Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?","volume":"18","year":"2003","journal-title":"Mov Disord"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1093\/brain\/awp209","article-title":"Longitudinal progression of sporadic Parkinson\u2019s disease: a multi-tracer positron emission tomography study","volume":"132","year":"2009","journal-title":"Brain"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0006-8993(03)02721-5","article-title":"Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study","volume":"982","year":"2003","journal-title":"Brain Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:05:33Z","timestamp":1750539933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003430","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}